Clinical Trial Update: Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma [Phase 4]

View source ↗

Summary

Phase 4 trial assessing immunogenicity of a pneumococcal vaccination strategy in adults treated for Non-Hodgkin lymphoma, comparing PCV13+PPV23 with Prevnar 20.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Pneumococcal Infection

Drugs mentioned

• Pneumovax 23 (Pneumococcal polysaccharide vaccine 23-valent)
• Prevnar 13 (pneumococcal conjugate vaccine)
• Prevnar 20 (20-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Poitiers University Hospital | Conditions: Vaccine, Streptococcus Pneumoniae | Phase 4 | Status: RECRUITING